secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARS Pharmaceuticals, Inc. (SPRY)
CIK:        0001671858
Form:       8-K
Filed at:   2022-10-21T23:59:59+00:00
Accession:  0001193125-22-266351
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA accepts ARS Pharma's NDA for neffy (epinephrine nasal spray) for allergic reactions
--------------------------------------------------------------------------------

- FDA accepted NDA for neffy (epinephrine nasal spray) for emergency treatment of allergic reactions including anaphylaxis in adults and children ≥30 kg.
- If approved, neffy would be first non-injectable treatment for type I allergic reactions in U.S.
- PDUFA target action date anticipated in mid-2023.
- NDA based on four registration studies showing pharmacokinetics comparable to injectable epinephrine; well-tolerated in over 500 individuals.
- Acceptance is a milestone for Silverback's proposed merger with ARS Pharma (previously announced).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671858/000119312522266351/0001193125-22-266351-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671858/000119312522266351/d305402d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-266351

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer